Delta-like ligand 4 and tumor treatment
10.3760/cma.j.issn.1673-422X.2011.05.010
- VernacularTitle:Delta样分子4与肿瘤治疗
- Author:
Qiqi HE
;
Zhongjin YUE
- Publication Type:Journal Article
- Keywords:
Neoplasms;
Vascular endothelial growth factors;
Therapy
- From:
Journal of International Oncology
2011;38(5):352-354
- CountryChina
- Language:Chinese
-
Abstract:
Up-regulation of DLL4 contributes to the angiogenesis in malignant tumors, and thus promote tumor growth. While down-regulation of DLL4 would cause antiangiogenesis and restrain tumor growth through forming a large number of no-function blood vessels. Thus it can be used in anti-VEGF tolerant tumors. Recently, DLL4 monoclonal antibody agents have entered clinic studies, and has achieved good curative effect in anti-VEGF tolerant tumors, but there are also some side effects. DLL4 would bring higher clinic value for cancer therapy if the side effects can be prevented effectively.
